Scilex Holding (SCLX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$31.6M

Revenue (quarter)

$7.6M

Revenue growth (year over year)

−22.78%

Gross profit (trailing twelve months)

$17.5M

Gross margin

55.50%

Net income (trailing twelve months)

−$464.6M

Net income (quarter)

−$115.0M

Net income growth (year over year)

−161.05%

Net margin

−1469.76%

Return on equity

—

EPS (trailing twelve months)

−$49.73

Book value per share

−$43.83

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

222.45%

Payout ratio

—

Dividend yield

—

Company profile

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

• Is Scilex Holding (SCLX) profitable?

  No. Scilex Holding reported a net loss of $464.6M over the trailing twelve months.

• How much revenue does Scilex Holding (SCLX) make?

  Scilex Holding generated $31.6M in revenue over the trailing twelve months, down 22.78% year over year.

• How do I buy stock in Scilex Holding (SCLX)?

  SCLX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.